Terms: = Head and neck cancer AND SEPT9, PNUTL4, 10801, ENSG00000184640, MSF1, KIAA0991, AF17q25, MSF, SeptD1, SINT1 AND Diagnosis
11 results:
1. Epigenetics in the diagnosis and prognosis of head and neck cancer: A systematic review.
Lim I; Tan J; Alam A; Idrees M; Brenan PA; Coletta RD; Kujan O
J Oral Pathol Med; 2024 Feb; 53(2):90-106. PubMed ID: 38316046
[TBL] [Abstract] [Full Text] [Related]
2. sept9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer.
Qian T; Zhou Z; Zhang Q; Liou YL; Zhou H
Medicine (Baltimore); 2023 Dec; 102(50):e36583. PubMed ID: 38115290
[TBL] [Abstract] [Full Text] [Related]
3. Circulating Cell-Free sept9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in head and neck Squamous Cell Carcinoma Patients.
Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
[TBL] [Abstract] [Full Text] [Related]
4. sept9_v2, frequently silenced by promoter hypermethylation, exerts anti-tumor functions through inactivation of Wnt/β-catenin signaling pathway via miR92b-3p/FZD10 in nasopharyngeal carcinoma cells.
Jiang Y; Liu L; Xiang Q; He X; Wang Y; Zhou D; Zou C; Chen Q; Peng M; He J; Jiang X; Xiang T; Yang Y
Clin Epigenetics; 2020 Mar; 12(1):41. PubMed ID: 32138771
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.
de Vos L; Gevensleben H; Schröck A; Franzen A; Kristiansen G; Bootz F; Dietrich D
Clin Epigenetics; 2017; 9():125. PubMed ID: 29213339
[TBL] [Abstract] [Full Text] [Related]
6. Free-Circulating Methylated DNA in Blood for diagnosis, Staging, Prognosis, and Monitoring of head and neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.
Schröck A; Leisse A; de Vos L; Gevensleben H; Dröge F; Franzen A; Wachendörfer M; Schröck F; Ellinger J; Teschke M; Wilhelm-Buchstab T; Landsberg J; Holdenrieder S; Hartmann G; Field JK; Bootz F; Kristiansen G; Dietrich D
Clin Chem; 2017 Jul; 63(7):1288-1296. PubMed ID: 28515105
[TBL] [Abstract] [Full Text] [Related]
7. Genome-wide screening of DNA methylation associated with lymph node metastasis in esophageal squamous cell carcinoma.
Nagata H; Kozaki KI; Muramatsu T; Hiramoto H; Tanimoto K; Fujiwara N; Imoto S; Ichikawa D; Otsuji E; Miyano S; Kawano T; Inazawa J
Oncotarget; 2017 Jun; 8(23):37740-37750. PubMed ID: 28465481
[TBL] [Abstract] [Full Text] [Related]
8. Promoter hypermethylation of
Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic and prognostic value of SHOX2 and sept9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257
[TBL] [Abstract] [Full Text] [Related]
10. Disruption of transforming growth factor-beta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis.
Bennett KL; Romigh T; Eng C
Cancer Res; 2009 Dec; 69(24):9301-5. PubMed ID: 19934318
[TBL] [Abstract] [Full Text] [Related]
11. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma.
Bennett KL; Karpenko M; Lin MT; Claus R; Arab K; Dyckhoff G; Plinkert P; Herpel E; Smiraglia D; Plass C
Cancer Res; 2008 Jun; 68(12):4494-9. PubMed ID: 18559491
[TBL] [Abstract] [Full Text] [Related]
